See more : Payoneer Global Inc. (PAYOW) Income Statement Analysis – Financial Results
Complete financial analysis of Taiko Pharmaceutical Co.,Ltd. (4574.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taiko Pharmaceutical Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ZIVO Bioscience, Inc. (ZIVOW) Income Statement Analysis – Financial Results
- YouYou Foods Co., Ltd. (603697.SS) Income Statement Analysis – Financial Results
- Triveni Turbine Limited (TRITURBINE.BO) Income Statement Analysis – Financial Results
- Taiwan Hopax Chems.Mfg.Co.,Ltd. (6509.TWO) Income Statement Analysis – Financial Results
- Clabo S.p.A. (CLA.MI) Income Statement Analysis – Financial Results
Taiko Pharmaceutical Co.,Ltd. (4574.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.seirogan.co.jp
About Taiko Pharmaceutical Co.,Ltd.
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.04B | 10.72B | 17.68B | 14.94B | 10.38B | 9.44B | 8.28B | 8.30B | 9.24B | 9.87B | 7.42B | 6.69B | 4.47B | 8.73B | 6.09B | 5.54B |
| Cost of Revenue | 3.96B | 7.97B | 5.26B | 4.36B | 3.22B | 2.89B | 2.71B | 2.56B | 2.35B | 2.68B | 2.41B | 2.20B | 1.58B | 2.44B | 1.64B | 1.59B |
| Gross Profit | 1.08B | 2.75B | 12.42B | 10.58B | 7.16B | 6.55B | 5.57B | 5.74B | 6.88B | 7.18B | 5.01B | 4.49B | 2.89B | 6.30B | 4.45B | 3.95B |
| Gross Profit Ratio | 21.41% | 25.63% | 70.24% | 70.82% | 69.01% | 69.42% | 67.24% | 69.18% | 74.51% | 72.81% | 67.53% | 67.10% | 64.56% | 72.09% | 73.01% | 71.33% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 410.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 3.19B | 4.70B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1.94B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 5.13B | 4.70B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 4.16B | 7.69B | 6.77B | -282.12M | -188.14M | -249.06M | -182.43M | -22.86M | 21.24M | 21.91M | 14.49M | 31.82M | 88.45M | 22.27M | -10.46M | 56.75M |
| Operating Expenses | 4.16B | 7.69B | 6.77B | 6.75B | 5.13B | 4.70B | 4.03B | 4.39B | 4.32B | 4.59B | 3.89B | 3.97B | 4.13B | 3.81B | 3.55B | 3.28B |
| Cost & Expenses | 8.12B | 15.67B | 12.03B | 11.11B | 8.35B | 7.58B | 6.74B | 6.95B | 6.68B | 7.28B | 6.29B | 6.18B | 5.71B | 6.24B | 5.20B | 4.87B |
| Interest Income | 5.00M | 3.00M | 6.70M | 5.61M | 4.22M | 1.19M | 1.73M | 3.66M | 6.95M | 4.44M | 3.12M | 2.23M | 2.62M | 32.09M | 35.66M | 40.17M |
| Interest Expense | 10.00M | 6.00M | 282.00K | 394.00K | 0.00 | 319.46M | 0.00 | 2.83M | 0.00 | 167.08M | 131.51M | 244.84M | 1.56B | 0.00 | 355.98M | 770.00K |
| Depreciation & Amortization | -671.00M | -620.00M | 272.53M | 495.20M | 460.89M | 453.66M | 444.85M | 350.52M | 280.61M | 258.69M | 250.53M | 258.84M | 241.26M | 212.21M | 176.43M | 164.34M |
| EBITDA | -3.75B | -5.57B | 5.92B | 4.07B | 2.39B | 2.33B | 1.91B | 1.66B | 2.86B | 2.98B | 1.48B | 918.23M | -197.74M | 2.64B | 1.22B | 833.26M |
| EBITDA Ratio | -74.40% | -51.94% | 33.50% | 27.22% | 23.03% | 24.64% | 23.02% | 20.02% | 30.93% | 30.19% | 19.99% | 13.72% | -4.42% | 30.27% | 20.09% | 15.03% |
| Operating Income | -3.08B | -4.95B | 5.65B | 3.82B | 2.03B | 1.86B | 1.55B | 1.35B | 2.56B | 2.59B | 1.12B | 515.00M | -1.24B | 2.49B | 894.37M | 672.14M |
| Operating Income Ratio | -61.09% | -46.16% | 31.96% | 25.61% | 19.56% | 19.68% | 18.65% | 16.25% | 27.70% | 26.25% | 15.12% | 7.70% | -27.80% | 28.50% | 14.68% | 12.13% |
| Total Other Income/Expenses | -1.79B | -3.94B | -276.72M | -320.25M | -45.00M | -304.31M | -54.37M | -156.17M | 199.40M | -37.12M | -20.44M | -100.45M | -753.33M | 100.29M | -203.26M | -72.47M |
| Income Before Tax | -4.87B | -8.89B | 5.37B | 3.50B | 1.99B | 1.55B | 1.49B | 1.19B | 2.76B | 2.55B | 1.10B | 414.55M | -2.00B | 2.59B | 691.12M | 599.67M |
| Income Before Tax Ratio | -96.61% | -82.90% | 30.39% | 23.46% | 19.14% | 16.45% | 18.00% | 14.36% | 29.86% | 25.88% | 14.84% | 6.20% | -44.65% | 29.65% | 11.35% | 10.82% |
| Income Tax Expense | 25.00M | 706.00M | 1.52B | 1.05B | 570.49M | 457.79M | 441.61M | 351.41M | 988.08M | 806.44M | 63.04M | -67.65M | 232.32M | 944.38M | 220.34M | 239.23M |
| Net Income | -4.89B | -9.59B | 3.85B | 2.45B | 1.42B | 1.09B | 1.05B | 840.11M | 1.77B | 1.75B | 1.04B | 482.20M | -2.23B | 1.65B | 470.78M | 360.44M |
| Net Income Ratio | -97.10% | -89.49% | 21.78% | 16.43% | 13.64% | 11.60% | 12.67% | 10.13% | 19.17% | 17.71% | 13.99% | 7.21% | -49.84% | 18.84% | 7.73% | 6.50% |
| EPS | -112.24 | -220.48 | 89.18 | 57.57 | 33.00 | 25.80 | 25.48 | 21.74 | 46.31 | 45.31 | 27.10 | 12.41 | -57.85 | 42.99 | 36.91 | 37.84 |
| EPS Diluted | -112.24 | -220.48 | 88.82 | 57.34 | 32.96 | 25.69 | 25.27 | 21.28 | 44.82 | 43.85 | 26.70 | 12.17 | -57.85 | 40.83 | 35.96 | 37.84 |
| Weighted Avg Shares Out | 43.60M | 43.51M | 43.19M | 42.62M | 42.90M | 42.45M | 41.18M | 38.64M | 38.23M | 38.56M | 38.28M | 38.85M | 38.51M | 38.27M | 12.76M | 9.52M |
| Weighted Avg Shares Out (Dil) | 43.60M | 43.51M | 43.36M | 42.79M | 42.95M | 42.63M | 41.53M | 39.49M | 39.50M | 39.84M | 38.86M | 39.62M | 38.51M | 40.30M | 12.76M | 9.52M |
Source: https://incomestatements.info
Category: Stock Reports